Novo Nordisk Wegovy's quarterly sales fell far short of expectations, and the stock price suffered a Waterloo at the opening
教们边束千
发表于 2024-8-7 17:51:37
1264
0
0
Caixin News Agency, August 7th (Editor Zhou Ziyi) - Danish pharmaceutical giant Novo Nordisk's star weight loss drug Wegovy's quarterly sales were lower than expected, causing concerns among investors who believe that Novo Nordisk's first mover advantage in the weight loss drug market is facing risks, and the company will also face more intense competition.
Novo Nordisk announced its second quarter results on Wednesday, August 7th. Both operating profit and net profit were lower than expected, and the company also lowered its annual operating profit forecast.
Calculated at a fixed exchange rate, its operating profit increased by 8% to 25.9 billion Danish kroner (equivalent to 3.8 billion US dollars) in the three months ending June, falling short of analysts' forecast of 27.3 billion Danish kroner; The net profit is 20.05 billion Danish kroner (equivalent to 2.93 billion US dollars), while the median analyst forecast is 20.9 billion Danish kroner.
Among them, Novo Nordisk's weight loss drug Wegovy saw a 53% increase in sales in the second quarter, reaching 11.66 billion kronor, far below the consensus expectation of 13.54 billion kronor summarized by analysts, but still higher than the 9.4 billion kronor in the first quarter.
On Wednesday (August 7th), Novo Nordisk's stock listed in Copenhagen experienced a cliff like decline, dropping nearly 7% at one point before recovering some of its losses. As of press time, it has fallen 4.84%.
Adjust the annual forecast
This report card shows a decline compared to Novo Nordisk's performance in the first quarter of this year in May. The company's net profit in the first quarter increased by 28% year-on-year, reaching 25.4 billion Danish kroner, and the company also slightly raised its forecast for sales and operating profit growth at that time.
On Wednesday, Novo Nordisk once again raised its full year sales growth forecast. Calculated at a fixed exchange rate, the currently released full year sales growth forecast for 2024 is 22% to 28%, compared to the previous sales growth forecast of 19% to 27%.
However, the company has recently lowered its operating profit forecast for 2024, stating that it currently expects a growth rate between 20% and 28%, instead of the previously expected range of 22% to 30%.
Regarding this, Novo Nordisk pointed out that due to the company's ongoing expansion of manufacturing capabilities, related costs have affected the quarterly profits. The company is spending a huge amount of money to increase Wegovy's production to meet the growing demand and compete with Eli Lilly. Lilly launched Wegovy's competitor, Zepbound, in the United States in December last year.
Greater competitive pressure
Since Novo Nordisk first launched Wegovy in the United States in June 2021, the company's stock price has risen by about 230%. However, since hitting a high in June this year, its stock price has fallen by 21%.
At present, Novo Nordisk is facing increasingly fierce competition in the field of weight loss drugs, including pressure from small companies and competition from pharmaceutical giants such as Eli Lilly and Roche. Novo Nordisk's first mover advantage in the rapidly growing obesity drug market is facing risks.
Last month, Roche released early trial data for its candidate weight loss drug CT-996. Experimental data shows that obese patients lost an average of 6.1% in weight after taking CT-996 tablets for 4 weeks. Based on new data, the market is optimistic about Roche's prospects, which is a major warning signal for Novo Nordisk.
Fortunately, in recent months, Novo Nordisk's weight loss drug Wegovy has also received encouraging news. The drug was approved in China in the second quarter of this year, opening the door to sales in the world's second-largest economy; The healthcare regulatory agencies in the UK and EU have also expressed their support for Wegovy, believing that it can reduce the risk of severe heart disease in overweight and obese adults.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- AI cloud leads Microsoft's performance, AI sales are expected to exceed billions of dollars in the next quarter
- Apple invests $1.5 billion to increase its stake in satellite communications, causing a surge in global satellite stock prices
- Buffett's net sales of stocks for the eighth consecutive quarter, Berkshire Hathaway's cash reserves hit a new high
- The stock price of Trump Media Technology Group rose by over 15% after the US stock market closed
- Ending four quarters of revenue decline, Tencent Music still needs to continue tapping into paying users
- The game did not drag down, and Bilibili achieved single quarter profitability for the first time
- Why did the stock price of Bilibili, which achieved profitability for the first time in the quarter, fall by more than 13%?
- Suddenly changed! Big news from chip giants! Samsung Electronics' stock price rises
- The stock price of Supermicro Computer has surged by 40%! What happened?
- Novo Nordisk's stock price returns to its starting point at the beginning of the year! Falling sales of weight loss drugs scare off investors
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 4 小时前
- 支持
- 反对
- 回复
- 收藏
-
アリババは、26億5000万ドルのドル建て優先無担保手形と170億元の人民元建て優先無担保手形の定価を発表した。ドル債の発行は2024年11月26日に終了する予定です。人民元債券の発行は2024年11月28日に終了する予定だ ...
- SOGO
- 前天 09:05
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 昨天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 昨天 14:29
- 支持
- 反对
- 回复
- 收藏